- Home
- CAPR vs VLGEA Comparison
CAPR vs VLGEA Comparison
Compare CAPR & VLGEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- VLGEA
- Stock Information
- Founded
- CAPR 2005
- VLGEA 1937
- Country
- CAPR United States
- VLGEA United States
- Employees
- CAPR N/A
- VLGEA N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- VLGEA Food Chains
- Sector
- CAPR Health Care
- VLGEA Consumer Staples
- Exchange
- CAPR Nasdaq
- VLGEA Nasdaq
- Market Cap
- CAPR 600.7M
- VLGEA 541.1M
- IPO Year
- CAPR N/A
- VLGEA N/A
- Fundamental
- Price
- CAPR $9.87
- VLGEA $39.39
- Analyst Decision
- CAPR Strong Buy
- VLGEA
- Analyst Count
- CAPR 8
- VLGEA 0
- Target Price
- CAPR $33.75
- VLGEA N/A
- AVG Volume (30 Days)
- CAPR 3.3M
- VLGEA 57.0K
- Earning Date
- CAPR 08-06-2025
- VLGEA 06-03-2025
- Dividend Yield
- CAPR N/A
- VLGEA 2.60%
- EPS Growth
- CAPR N/A
- VLGEA 12.55
- EPS
- CAPR N/A
- VLGEA 3.80
- Revenue
- CAPR $17,363,588.00
- VLGEA $2,299,253,000.00
- Revenue This Year
- CAPR $258.96
- VLGEA N/A
- Revenue Next Year
- CAPR $8.02
- VLGEA N/A
- P/E Ratio
- CAPR N/A
- VLGEA $10.15
- Revenue Growth
- CAPR N/A
- VLGEA 3.94
- 52 Week Low
- CAPR $3.52
- VLGEA $24.90
- 52 Week High
- CAPR $23.40
- VLGEA $40.15
- Technical
- Relative Strength Index (RSI)
- CAPR 45.24
- VLGEA 57.79
- Support Level
- CAPR $6.07
- VLGEA $38.03
- Resistance Level
- CAPR $11.58
- VLGEA $39.46
- Average True Range (ATR)
- CAPR 1.59
- VLGEA 0.78
- MACD
- CAPR -0.23
- VLGEA 0.05
- Stochastic Oscillator
- CAPR 44.57
- VLGEA 68.31
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About VLGEA Village Super Market Inc.
Village Super Market Inc operates a chain of ShopRite supermarkets, a few of which are in northern New Jersey, southern New Jersey, Maryland, and in northeastern Pennsylvania. The company is a member of Wakefern Food Corporation (Wakefern), a retailer-owned food cooperative and owner of the ShopRite name. It consists of one operating segment, the retail sale of food and nonfood products.